Article
Autolus to ax 20% of staff, offload asset as lead CAR-T nears pivotal data
Rating:
0.0
Views:
40
Likes:
1
Library:
1
Autolus Therapeutics is set to reduce its headcount by around 20% and seek a partner for one of its dual-targeted CAR-T candidates. The changes will increase Autolus' focus on CD19 CAR-T cell therapy AUTO1 ahead of the anticipated delivery of pivotal data on the candidate next year.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value